Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “CAR-T Cell Therapy”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Early research (Phase 1)Looking for participantsNCT06313957
What this trial is testing

LUCAR-20SP in Subjects With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma

Who this might be right for
Relapsed B-cell Non-Hodgkin LymphomaRefractory B-cell Non-Hodgkin Lymphoma
Peking University Cancer Hospital & Institute 42
Testing effectiveness (Phase 2)Looking for participantsNCT05243212
What this trial is testing

Study of CAR-BCMA, a Chimeric Antigen Receptor T Cell (CAR-T) Therapy Directed Against BCMA in Subjects With Multiple Myeloma

Who this might be right for
Multiple MyelomaRelapse Multiple Myeloma
Sheba Medical Center 75
Testing effectiveness (Phase 2)Looking for participantsNCT05648019
What this trial is testing

CD19-Directed Chimeric Antigen Receptor (CAR) T-Cell Therapy for Relapsed/Refractory B-Lineage Leukaemia / Lymphoma - A Feasibility Protocol

Who this might be right for
Lymphoblastic LeukemiaLymphoblastic Leukemia in ChildrenLymphoblastic Leukemia, Acute Adult+3 more
KK Women's and Children's Hospital 40
Early research (Phase 1)Looking for participantsNCT07200102
What this trial is testing

Selinexor Maintenance Post CAR-T Cell Therapy for Multiple Myeloma

Who this might be right for
Multiple Myeloma
Washington University School of Medicine 20
Testing effectiveness (Phase 2)Looking for participantsNCT05260957
What this trial is testing

CAR-T Cell Therapy, Mosunetuzumab and Polatuzumab for Treatment of Refractory/Relapsed Aggressive Non-Hodgkin's Lymphoma (NHL).

Who this might be right for
Refractory Non-Hodgkin LymphomaRelapsed Non Hodgkin LymphomaAggressive Non-Hodgkin Lymphoma
Lazaros Lekakis 22
Early research (Phase 1)Looking for participantsNCT06186401
What this trial is testing

Anti-EGFRvIII synNotch Receptor Induced Anti-EphA2/IL-13Ralpha2 CAR (E-SYNC) T Cells

Who this might be right for
EGFR Gene MutationGlioblastomaMGMT-Unmethylated Glioblastoma+1 more
Hideho Okada, MD, PhD 20
Early research (Phase 1)Looking for participantsNCT06718738
What this trial is testing

Clinical Study of IM96 CAR-T Cell Therapy in Patients With Advanced Colorectal Cancer

Who this might be right for
Colorectal Cancer (CRC)
Beijing Immunochina Medical Science & Technology Co., Ltd. 9
Early research (Phase 1)WithdrawnNCT07297160
What this trial is testing

CD70.CAR for CD70+ Lymphoma, Myeloma and Solid Tumors

Who this might be right for
LymphomaMyelomaSolid Tumors+2 more
Baylor College of Medicine
Testing effectiveness (Phase 2)Looking for participantsNCT06238648
What this trial is testing

Epcoritamab Compared to Observation for Treating B-cell Lymphoma Patients Not in Complete Remission After CD19-directed CAR-T Therapy

Who this might be right for
Diffuse Large B-Cell Lymphoma, Not Otherwise SpecifiedPrimary Mediastinal Large B-Cell LymphomaTransformed Indolent B-Cell Non-Hodgkin Lymphoma to Diffuse Large B-Cell Lymphoma
Academic and Community Cancer Research United 120
Very early researchStudy completedNCT04650724
What this trial is testing

Clinical Study of T Cell Infusion Targeting BCMA Chimeric Antigen Receptor

Who this might be right for
Multiple Myeloma
PersonGen BioTherapeutics (Suzhou) Co., Ltd. 3
Very early researchUnknownNCT03910842
What this trial is testing

Treatment of Children CD19+ Leukemia and Non-Hodgkin Lymphoma With CD19-TriCAR-T/SILK Cell Therapy

Who this might be right for
Non-Hodgkin Lymphoma of IntestineLeukemia
Timmune Biotech Inc. 12
Early research (Phase 1)Not Yet RecruitingNCT07539610
What this trial is testing

Evaluation of the Safety and Efficacy of Sup19 CAR-T Cells in Patients With Previously Failed CD19-Targeted Therapy or CD19-Weakly Expressed Hematologic Tumors

Who this might be right for
B-Acute Lymphoblastic LeukemiaB Acute Lymphoblastic Leukemia/Lymphoma
Institute of Hematology & Blood Diseases Hospital, China 9
Not applicableNot Yet RecruitingNCT07008872
What this trial is testing

CD7 CAR-T Cell Therapy Targeting CD7-positive Relapsed/Refractory T Cell Lymphoma/Acute Leukemia

Who this might be right for
CD7+ LymphomaCD7+ Acute Leukemia
Qi deng 40
Early research (Phase 1)Looking for participantsNCT06326021
What this trial is testing

Optimised CD33 (FL-33) CAR T Therapy for Refractory/Relapsed Acute Myeloid Leukaemia

Who this might be right for
Refractory/Relapsed Acute Myeloid Leukaemia
Beijing GoBroad Hospital 27
Very early researchNot Yet RecruitingNCT07066436
What this trial is testing

ImmunoMRI for Assessment of Tumor-associated Macrophages

Who this might be right for
DLBCL - Diffuse Large B Cell Lymphoma
Medical University of Vienna 60
Early research (Phase 1)Active Not RecruitingNCT05878184
What this trial is testing

Study Evaluating SC291 in Subjects With r/r B-cell Malignancies (ARDENT)

Who this might be right for
Non Hodgkin LymphomaChronic Lymphocytic Leukemia
Sana Biotechnology 16
Early research (Phase 1)Study completedNCT02215967
What this trial is testing

Study of T Cells Targeting B-Cell Maturation Antigen for Previously Treated Multiple Myeloma

Who this might be right for
Myeloma, Plasma-CellMyeloma-Multiple
National Cancer Institute (NCI) 30
Testing effectiveness (Phase 2)Not Yet RecruitingNCT06777264
What this trial is testing

Inaticabtagene Autoleucel (Inati-cel; CNCT19) Treatment for Newly Diagnosed B-cell ALL Patients in CR1

Who this might be right for
Acute Lymphoblastic LeukemiaB Cell ALL
First Affiliated Hospital of Zhejiang University 20
Large-scale testing (Phase 3)Active Not RecruitingNCT05257083
What this trial is testing

Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) Followed by Ciltacabtagene Autoleucel Versus Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) Followed by Autologous Stem Cell Transplant (ASCT) in Participants With Newly Diagnosed Multiple Myeloma

Who this might be right for
Multiple Myeloma
Stichting European Myeloma Network 759
Testing effectiveness (Phase 2)Looking for participantsNCT07009002
What this trial is testing

BCOR and ZC3H12 Genes Knock-out CD19-targeting CAR-T Cell Therapy in r/r B Cell Lymphoma

Who this might be right for
B Cell Lymphoma
Chinese PLA General Hospital 30
Next Page